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In July 2018, olaparib, an oral poly adenosine diphosphate-ribose polymerase(PARP)inhibitor, was approved for the first time in Japan as a companion diagnostic drug for the treatment of recurrent breast cancer in BRCA-positive patients. Genetic testing had been offered only to clients who met the eligibility criteria for the test, and the decision whether or not to receive the test was based on their medical and family history, tumor characteristics, and the client's preference. With the approval of olaparib as a companion diagnostic drug, genetic testing has become a part of the standard treatment protocol. Modern technology has made multiple genetic testing possible in one setting. It is therefore necessary for medical practitioners to have the knowledge and ability to take care for familiar tumors. It may be difficult to understand all the available information on genetics, but an individualized approach for each patient would be necessary in the future. Medical practitioners involved in the treatment of such patients would need adequate knowledge on genetics and genetic counseling, as well as the ability to educate and provide information to the patients and their families. If a more specialized approach is necessary, referral to an institution with a clinical genetics department is essential.